Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured

Published in Urology and

Journal Scan / Research · October 05, 2018

Second-Line Chemotherapy vs an Androgen Receptor–Targeted Agent for Metastatic Castration-Resistant Prostate Cancer

Urologic Oncology: Seminars and Original Investigations

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Joshua Cohn MD, FPMRS

David Jarrard MD

Urologic Oncology: Seminars and Original Investigations

Real-World Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Second-Line Chemotherapy Versus an Alternative Androgen Receptor-Targeted Agent (ARTA) Following Early Progression on a First-Line ARTA in a US Community Oncology Setting

Urol. Oncol 2018 Sep 07;[EPub Ahead of Print], Wk Oh, WY Cheng, R Miao, et al

Advanced Prostate Cancer

Second-Line Chemotherapy vs an Androgen Receptor–Targeted Agent for Metastatic Castration-Resistant Prostate Cancer

Additional Info

Real-World Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Second-Line Chemotherapy Versus an Alternative Androgen Receptor-Targeted Agent (ARTA) Following Early Progression on a First-Line ARTA in a US Community Oncology Setting

Further Reading

Contribution of Gleason Pattern 4 Prostate Tissue to Blood PSA Levels

The Impact of Local Staging of Prostate Cancer Determined on MRI or DRE at Time of Radical Prostatectomy on Progression-Free Survival

Treatment Decision Regret in Long-Term Prostate Cancer Survivors After Radical Prostatectomy

Systemic Inflammation Response Index as an Independent Predictive Factor for Survival Outcomes in Patients With Bladder Cancer

Multiple Recurrences and Disease Progression in Patients With Intermediate-Risk NMIBC

Intracavernosal Injection of Botulinum Toxin in the Treatment of Erectile Dysfunction

Median 5-Year Outcomes of Primary Focal IRE for Localised Prostate Cancer

Log Odds of Positive Lymph Nodes as an Independent Predictor of Overall Survival After Radical Cystectomy in Patients With Urothelial Bladder Cancer

Shifting Risk-Stratified Early Prostate Cancer Detection to a Primary Healthcare Setting

Relationship Between the Number of Lymph Nodes Dissected and Prognosis in Patients With MIBC in the Era of Neoadjuvant Chemotherapy

Novel Potential Risk Factors for Postoperative Complications Following Primary Hypospadias Repair

Recently Updated